Full Breakdown
New Nonprofit Aims to Turn Gene Editing for Rare Diseases into Routine Procedure
7/22/2026, 4:46:18 AM
Launch of the Center for Therapeutic Genetics
A partnership between the Broad Institute, Boston Children’s Hospital and the Jackson Laboratory announced the creation of the Center for Therapeutic Genetics (CTG), a nonprofit dedicated to developing precision gene-editing treatments for rare diseases. The center received an initial $34.5 million award from ARPA-H and will begin by targeting rare genetic epilepsies. CTG is still in its founding phase and is not yet accepting patient referrals.
Background & Context
Rare diseases affect an estimated 400 million people worldwide and 25-30 million in the United States, with roughly half of patients being children. Fewer than 5 percent of the more than 10,000 identified conditions have an approved therapy. Advances in CRISPR, base editing and prime editing now make it possible to edit disease-causing genes, but the lack of scalable infrastructure keeps most patients without access.
Key Figures & Groups
- David Liu – Gene-editing researcher, Broad Institute.
- Wendy Chung, MD, PhD – Chief of Pediatrics, Boston Children’s Hospital.
- Winston Yan, MD, PhD – Founding director, CTG.
- Timothy Yu, MD, PhD – Attending physician, Boston Children’s Hospital and founding partner, CTG.
- Pamela Gavin – CEO, National Organization for Rare Disorders.
Data & Statistics
- Global prevalence: ~400 million people.
- U.S. prevalence: 25-30 million; one-in-10 Americans.
- Therapeutic gap: >10,000 rare diseases, <5 percent with approved treatments.
Why It Matters
CTG’s model treats gene-editing interventions as standardized clinical procedures rather than bespoke drug products. By creating reusable platforms—disease models, manufacturing pipelines, safety data and clinical protocols—the center aims to lower costs, accelerate development and enable regulatory pathways similar to those for organ transplants or surgeries.
Official Statements & Responses
Winston Yan emphasized that the center will not rely on disease-specific family funding, instead seeking philanthropic support to prioritize conditions that can advance the field quickly. Timothy Yu added that the goal is to avoid a waiting-list model and to raise money for the broader field. Wendy Chung noted that the current barrier is the lack of infrastructure to deliver treatments at scale.
Verbatim Quotes
- “Our model is not to be family-funded for particular diseases,” — Timothy Yu
- “We’re excited about what they’re building because it addresses one of the greatest unmet needs in rare disease,” — Pamela Gavin, CEO of NORD
What’s Next
CTG plans to develop modular, programmable medicines that can be customized for each patient, share methods and data with other institutions, and eventually offer a “standard of care” pathway for families who receive a genetic diagnosis. The center will continue to build disease models, safety data and manufacturing processes, with the expectation that future regulatory approvals will follow the procedural model used for surgeries rather than requiring separate drug approvals for each indication.
